Company & Sponsor Intelligence

Marinus Pharmaceuticals

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials5

Recruiting0

Completed4

Countries1

Therapeutic footprint

epilepsyneurodevelopmental_otherother_neurology

Indexed studies

NCT01725152Ganaxolone Treatment in Children With Fragile X Syndrome
neurodevelopmental_other · United StatesPHASE2

NCT05604170Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
epilepsy · United StatesPHASE3

NCT04285346Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)
other_neurology · United StatesPHASE2

NCT00441896A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms
other_neurology · United StatesPHASE2

NCT03350035Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus
epilepsy · United StatesPHASE2

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →